These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32251732)

  • 21. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.
    Kim Y; Liu H; Galasiti Kankanamalage AC; Weerasekara S; Hua DH; Groutas WC; Chang KO; Pedersen NC
    PLoS Pathog; 2016 Mar; 12(3):e1005531. PubMed ID: 27027316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [De første kliniske data fra RASi-behandlede indlagte patienter med COVID-19 kommer nu, og vi skal ikke ændre medicinering].
    Madsen PL
    Ugeskr Laeger; 2020 May; 182(20):. PubMed ID: 32400381
    [No Abstract]   [Full Text] [Related]  

  • 23. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
    Brogi S; Calderone V
    Br J Clin Pharmacol; 2020 Jun; 86(6):1178-1179. PubMed ID: 32359080
    [No Abstract]   [Full Text] [Related]  

  • 24. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic.
    Qian K; Hu S
    MAbs; 2020; 12(1):e1782600. PubMed ID: 32546047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The therapeutic potential of targeting ACE2 in COVID-19.
    Elmorsi R
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9744-9747. PubMed ID: 33015820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
    [No Abstract]   [Full Text] [Related]  

  • 28. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances of therapeutic targets and potential drugs of COVID-19.
    Zhang W; Zhang P; Wang G; Cheng W; Chen J; Zhang X
    Pharmazie; 2020 May; 75(5):161-163. PubMed ID: 32393419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
    Sternberg A; McKee DL; Naujokat C
    Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alkamides and Piperamides as Potential Antivirals against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Gutierrez-Villagomez JM; Campos-García T; Molina-Torres J; López MG; Vázquez-Martínez J
    J Phys Chem Lett; 2020 Oct; 11(19):8008-8016. PubMed ID: 32840378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral activity of itraconazole against type I feline coronavirus infection.
    Takano T; Akiyama M; Doki T; Hohdatsu T
    Vet Res; 2019 Jan; 50(1):5. PubMed ID: 30658691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. H
    Yang G
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
    Cava C; Bertoli G; Castiglioni I
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19.
    McPherson SW; Keunen JE; Bird AC; Chew EY; van Kuijk FJ
    Am J Ophthalmol; 2020 Aug; 216():A5-A6. PubMed ID: 32505362
    [No Abstract]   [Full Text] [Related]  

  • 39. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.